About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

RECRUITINGNCT05866796

Serum GLYcomics to Predict Graft Loss and Mortality After Liver Transplantation

The first 12 months after liver transplantation (LT) are decisive in posttransplant outcome, as almost half of deaths and two thirds of graft loss requiring retransplant occur in the first year after ...

Lead sponsor: University Hospital, Ghent•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Start Free Trial

Contacts

Xavier Verhelst, MD, PhD

CONTACT

0032 9 332 23 71 xavier.verhelst@uzgent.be

Lorenz Grossar, MD

CONTACT

0032 494 088 789 lorenz.grossar@uzgent.be

Sponsors

Lead Sponsor

University Hospital, Ghent

Collaborators

Fund for Scientific Research, Flanders, Belgium
University Hospital, Antwerp
Universitaire Ziekenhuizen KU Leuven
Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Signed and dated patient informed consent document
•Age ≥ 18 years
•Ability to comply with protocol-specified evaluations and scheduled visits
•Diagnosis of end-stage liver disease, primary hepatic malignancy meeting the Milan criteria for liver transplantation, or acute hepatic failure
•Eligible for liver transplantation and/or active on the waiting list for liver transplantation. Individuals eligible and/or active on the waiting list for multiple organ transplantation including the liver (eg. Combined liver and kidney transplantation, or intestinal transplantation) are also eligible for inclusion.
•Consulted the department of Gastroenterology and Hepatology at Ghent University Hospital

Exclusion Criteria

•\- Transplantation of one or more organs not including the liver

Related studies

Active Not Recruiting

Cytokeratin 18 Non-invasive Biomarker for Rejection in Liver Transplant Patients

NCT06153641 · Liver Transplant Rejection, Liver Transplant Failure and Rejection

SUSPENDEDPhase 4

Parenteral Ascorbic Acid Repletion in TransplantatIon

NCT04756063 · Liver Transplant Failure and Rejection

Analysis of Donor-derived Cell Free DNA in Liver Transplant Patients

NCT06225206 · Liver Transplant Failure

Mortality, Morbidity and Risk Factors of Liver Retransplantation

NCT04789213 · Liver Transplant; Complications, Liver Transplant Rejection, and more

Prospective Validation of Circulating Tumor Cells & Circulating Endothelial Cells as Biomarkers in Renal Cancer

NCT02499458 · Clear Cell Renal Cancer, Circulating Tumor Cells, and more

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: May 16, 2024Terms

Trial snapshot

StatusRECRUITING

Phase—

Enrollment600

Start dateApr 2023

Last updatedMay 16, 2024

Condition

Liver Transplant Failure Prognostic Biomarkers

Locations shown

Xavier Verhelst

Ghent, Flanders

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 16, 2024Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions